Epirus signs biosimilars deal with Chinese partner
This article was originally published in Scrip
Executive Summary
Boston-based Epirus Biopharmaceuticals has made its second recent advance in the Asian region – this time with a broad-based deal for antibody-based drugs with its investor and Chinese biotech, Livzon Mabpharm.